Data presented at the European Renal Association meeting today suggest that Novartis AG is heading to market with two therapies for different rare kidney diseases. Fabhalta (iptacopan) and atrasentan have shown respectable reductions in proteinuria in their respective trials, likely satisfying regulators’ requirements.
Novartis Aims To Dominate Rare Renal Disorders
Fabhalta and atrasentan are odds-on for approval in C3 glomerulopathy and IgA nephropathy, respectively, but commercial success might be harder to come by.
